More unit IPOs an option for evolving GlaxoSmithKline

GlaxoSmithKline could consider more partial public share offerings for component units as it evolves in the coming years, potentially pointing to a break-up of the group if this offers value to shareholders.

Read Full Article

GSK's nicotine patches and gum feel the heat from e-cigarettes

GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said.

Read Full Article

Novartis says Alcon's Travatan receives EU approval

Swiss pharmaceutical group Novartis said on Tuesday the European Commission had approved an additional treatment for its eyecare unit Alcon's Travatan treatment for glaucoma, a chronic, sight-threatening eye disease.

Read Full Article

Novartis psoriasis drug tops J&J's Stelara in late-stage study

Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara.

Read Full Article

GlaxoSmithKline drops plan to sell off older drugs business

GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers.

Read Full Article

First gene therapy drug sets million-euro price record

The Western world's first gene therapy drug is set to go on sale in Germany with a 1.1 million euro ($1.4 million) price tag, a new record for a medicine to treat a rare disease.

Read Full Article

Novartis says three executives to leave after GSK, Lilly deals

Swiss drugmaker Novartis AG (NOVN.VX) said three members of its executive committee would leave the company following the completion of transactions with GlaxoSmithKline (GSK.L) and Eli Lilly (LLY.N) to divest three units.

Read Full Article

EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal: sources

EU antitrust regulators will open an extensive probe into Zimmer's (ZMH.N) $13.4 billion bid for Biomet, concerned that the creation of the world's second-largest orthopedic products group may hurt competition, three people familiar with the matter said on Thursday.

Read Full Article

After China, GlaxoSmithKline faces pressure for change

GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back skeptical investors.

Read Full Article

'Back to normal' for AstraZeneca CEO, despite Pfizer rumors

Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Instead, he has spent the last three days immersed in heart science in Barcelona.

Read Full Article

Sanofi looking growth in Africa through acquisitions

Sanofi is looking to grasp a good hold in Africa through acquisition of business units, according to the firm's CEO Chris Viehbacher who told Reuters.

Read Full Article

Vernalis and Asahi Kasei Pharma Achieve Milestone

Vernalis is pleased to announce the achievement of the first milestone in its research collaboration with Asahi Kasei Pharma (AKP).

Read Full Article

Swiss drugmaker Novartis to acquire CoStim Pharmaceuticals Inc

Switzerland-based drug manufacturer Novartis will be buying closely-held Massachusetts-based biotechnology firm so it will grow its range of immunotherapeutics products to treat cancer, Bloomberg reported.

Read Full Article

European drugmakers flock to Boston in search for deals- report

Drugmakers from Europe are getting lured to the Boston-Cambridge area as the biotechnology boom makes it the envy of other biotechnolgy hubs in the world, Bloomberg reported.

Read Full Article

Boehringer subsidiary hires Bank of America to explore sale of injectable drugs business

Ben Venue Laboratories, a subsidiary of German Boehringer Ingelheim in the US, has engaged Bank of American Merill Lynch to advise it on a proposed sale of its sterile injectable drugs business.

Read Full Article
1 2

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics